Filtered By:
Specialty: Hematology
Source: Thrombosis Research
This page shows you your search results in order of relevance. This is page number 15.
Order by Relevance | Date
Total 221 results found since Jan 2013.
Low molecular weight heparin anti-Xa assays can identify patients with clinically important apixaban and rivaroxaban drug levels
Direct oral anticoagulants (DOACs) do not require routine coagulation monitoring but measuring plasma drug levels may be helpful in specific circumstances. For example, patients with DOAC drug levels below 30 to 50 ng/mL are unlikely to benefit from anticoagulant reversal strategies before an urgent medical procedure or to treat major bleeding [1] or may be suitable candidates for systemic thrombolysis in the setting of acute ischemic stroke [2].
Source: Thrombosis Research - May 12, 2022 Category: Hematology Authors: Siraj Mithoowani, Karen A. Moffat, Akash Gupta, Stephen A. Carlino, Mark A. Crowther Tags: Letter to the Editors-in-Chief Source Type: research
Effectiveness and safety of edoxaban therapy in daily-care patients with atrial fibrillation. Results from the DRESDEN NOAC REGISTRY
Edoxaban is a non-vitamin K dependent oral anticoagulant (NOAC) licensed for stroke prevention in atrial fibrillation (SPAF). Outcome data on clinical effectiveness and safety in routine care are increasing.
Source: Thrombosis Research - May 22, 2022 Category: Hematology Authors: Christina K öhler, Luise Tittl, Sandra Marten, Christiane Naue, Marianne Spindler, Laura Stannek, Kristina Fache, Jan Beyer-Westendorf Tags: Letter to the Editors-in-Chief Source Type: research
The long haul COVID-19 arterial thrombosis
The presence of a coexisting hypercoagulable state associated with Covid-19 infection has gained attention and several studies have already described acute limb ischemia (ALI) and peripheral arterial disease in critically ill patients, as well as coronary artery disease and ischemic stroke as manifestations usually associated with respiratory distress. Actually no information is currently available on how long inflammation and thrombotic derangements can last after recovery from Covid-19 symptoms and which patients are prone to develop acute arterial thrombosis.
Source: Thrombosis Research - July 26, 2022 Category: Hematology Authors: Maria Pia Borrelli, Adelaide Buora, Paolo Frigatti Tags: Letter to the Editors-in-Chief Source Type: research
Impact of stroke on survival in patients with cancer
Thromboembolic events, including venous thromboembolism (VTE) and arterial thromboembolism (ATE), are significant concerns for patients with cancer as they can interrupt or delay essential cancer treatments and worsen outcomes [1]. Previous studies have suggested that VTE is associated with an increased risk of mortality in patients with cancer [2 –5]. Meanwhile, few studies have investigated the relationship between ATE and outcomes in patients with cancer. Grilz et al. assessed the effect of ATE on 2-year survival in such patients and reported that ATE was associated with a 3.2-fold increased risk of all-cause mortality [6].
Source: Thrombosis Research - January 6, 2023 Category: Hematology Authors: Yasufumi Gon, Tsutomu Sasaki, Tomohiro Kawano, Shuhei Okazaki, Kenichi Todo, Toshihiro Takeda, Yasushi Matsumura, Hideki Mochizuki Tags: Letter to the Editors-in-Chief Source Type: research
A response to a letter to the editor TR-D-22-00887
In this study, we found that among patients with minor acute ischemic stroke due to large vessel occlusions (AIS-LVO), direct endovascular thrombectomy (EVT), compared with bridging therapy, met the prespecified statistical threshold for noninferiority for the 3-month prognosis [1].
Source: Thrombosis Research - January 16, 2023 Category: Hematology Authors: Wen-Jun Tu, Yicheng Xu Tags: Letter to the Editors-in-Chief Source Type: research
Recurrent thrombotic events after disappearance of antiphospholipid autoantibodies: A long-term longitudinal study in patients with antiphospholipid syndrome
Antiphospholipid syndrome (APS) is an autoimmune disease characterized by the occurrence of thrombosis and/or pregnancy morbidity related to the presence of persistent antiphospholipid autoantibodies (aPL) [1]. The most frequent clinical manifestations of APS are thrombotic events and death may be caused by stroke, myocardial infarction, pulmonary embolism or catastrophic APS [2]. APS treatment is based on long term anticoagulation [3].
Source: Thrombosis Research - February 9, 2023 Category: Hematology Authors: Thomas Ballul, Arthur Mageau, Pascale Roland Nicaise, Nadine Ajzenberg, Andrey Strukov, Antoine Dossier, Diane Rouzaud, Thomas Papo, Karim Sacr é Tags: Letter to the Editors-in-Chief Source Type: research
DOACs plasma levels in relation to clinical outcome. How far have wecome?
Direct oral anticoagulants (DOACs) are the preferred treatment for prevention of ischemic stroke (IS) and systemic embolism (SE) in nonvalvular atrial fibrillation (NVAF) and treatment or prevention of venous thromboembolism (VTE) [1]. DOACs are administered in fixed doses and do not require routine laboratory monitoring [2]. Nonetheless, high interindividual variability of DOAC blood levels has been reported and the correlation between DOAC plasma levels and clinical outcome is still a grey area.
Source: Thrombosis Research - March 3, 2023 Category: Hematology Authors: Rosa Talerico, Roberto Pola, Menno Volkert Huisman, Frederikus Albertus Klok Tags: Letter to the Editors-in-Chief Source Type: research
DOACs plasma levels in relation to clinical outcome. How far have we come?
Direct oral anticoagulants (DOACs) are the preferred treatment for prevention of ischemic stroke (IS) and systemic embolism (SE) in nonvalvular atrial fibrillation (NVAF) and treatment or prevention of venous thromboembolism (VTE) [1]. DOACs are administered in fixed doses and do not require routine laboratory monitoring [2]. Nonetheless, high interindividual variability of DOAC blood levels has been reported and the correlation between DOAC plasma levels and clinical outcome is still a grey area.
Source: Thrombosis Research - March 3, 2023 Category: Hematology Authors: Rosa Talerico, Roberto Pola, Menno Volkert Huisman, Frederikus Albertus Klok Tags: Letter to the Editors-in-Chief Source Type: research
Hypercoagulability evaluation in congenital red blood cell disorders using thrombin generation assay
Congenital red blood cell (RBC) disorders are common diseases in the general population. The main outcomes are increased deformability due to erythrocyte instability, increased susceptibility to oxidative stress, and intravascular hemolysis. Hemolytic anemia is associated with thrombosis risk [1]. Main mechanisms are related to hypercoagulability, endothelial damage, altered blood flow, and decreased nitric oxide. Hypercoagulability is well documented in sickle cell disease (SCD) [2]. However, other RBC disorders are associated with pulmonary embolism, hypertension, non-ischemic stroke, and adverse vascular manifestations ...
Source: Thrombosis Research - March 23, 2023 Category: Hematology Authors: Guillaume Feugray, Maximilien Grall, C écile Dumesnil, Ygal Benhamou, Valery Brunel, Véronique Le Cam Duchez, Agnès Lahary, Paul Billoir Tags: Letter to the Editors-in-Chief Source Type: research
Clinical effectiveness and safety of edoxaban in obese patients — Results of the prospective Dresden NOAC Registry (NCT01588119)
Edoxaban is a direct factor Xa inhibitors approved for stroke prevention in atrial fibrillation (SPAF) and for venous thromboembolism (VTE) treatment. Edoxaban is given in a fixed dosing regimen (with recommended dose reductions for patients with renal impairment or body weight
Source: Thrombosis Research - June 2, 2023 Category: Hematology Authors: Luise Tittl, Christina K öhler, Sandra Marten, Christiane Naue, Kristina Fache, Laura Stanneck, Thomas Schreier, Jan Beyer-Westendorf Tags: Letter to the Editors-in-Chief Source Type: research
Barriers and facilitators for adherence to direct oral anticoagulants in patients with atrial fibrillation: A qualitative approach
Direct oral anticoagulants (DOACs) are the cornerstone for stroke prevention in patients with atrial fibrillation (AF) [1]. DOAC non-adherence and discontinuation have been associated with higher thromboembolic and mortality risks [2]. Until now, studies trying to optimise adherence to DOACs show disappointing results with limited effectiveness of interventions [3]. An explanation might be that medication (non-)adherence is a very complex behaviour in which different determinants, varying between patients, play a role.
Source: Thrombosis Research - June 14, 2023 Category: Hematology Authors: Andreas Capiau, Maxim Grymonprez, Sophie Scheire, Yenna Faute, Lies Lahousse, Els Mehuys, Tine De Backer, Koen Boussery Tags: Letter to the Editors-in-Chief Source Type: research
